New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2013
09:19 EDTPRANPrana says there is no placebo group in its IMAGINE AD Extension trial
Prana Biotechnology provided an update of its IMAGINE Alzheimer's Disease, or AD, Extension trial. In July Prana announced that the Austin Health Human Research Ethics Committee, or HREC, approved a 12-month open label extension study for patients completing the double- blind placebo-controlled IMAGINE trial. There is no placebo group in the Extension trial. All participants receive a once daily dose of 250mg of PBT2. PBT2 is Prana's drug in Phase 2 development for Alzheimer's and Huntington's diseases.
News For PRAN From The Last 14 Days
Check below for free stories on PRAN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PRAN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use